Guideline documents from multiple societies converged on a limited set of diagnostic tools for rheumatoid arthritis-associated interstitial lung disease. The study team observed that guidelines emphasized high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and multidisciplinary evaluation as the backbone of diagnosis. Short sentences clarify the point: HRCT is central. The cohorts and panels cited by the authors prioritized imaging and functional assessment before assigning a working diagnosis. Data indicated that multidisciplinary discussion—bringing together rheumatology, pulmonology, and radiology expertise—was recommended across the guideline groups reviewed.
The authors found notable divergence in screening recommendations. ERS/EULAR and ACR/CHEST favored a risk-based screening approach, directing clinicians to focus surveillance on patients with clinical or serologic risk markers. ALAT recommended a broader screening strategy; the guideline group proposed lung ultrasound as an adjunct screening tool, explicitly stating that it should not replace HRCT. The review team noted that details on exact screening thresholds, risk markers, or implementation pathways were not uniformly reported across the guideline documents.
Monitoring schedules showed variability. ACR/CHEST provided implementation guidance that included PFTs every 3–12 months during the first year and repeat HRCT imaging when clinically indicated. ERS/EULAR proposed a tighter window early on, recommending PFTs every 3–6 months in the first years and periodic HRCT surveillance. The investigators reported that these interval differences reflect differing panel emphases on early detection of progression versus resource stewardship. The guideline source did not offer a single, harmonized monitoring algorithm applicable to all clinical settings.
Treatment guidance produced the widest disagreement. ACR/CHEST issued conditional recommendations for several immunosuppressive agents as first-line ILD therapies, listing mycophenolate, rituximab, azathioprine, and cyclophosphamide. By contrast, ALAT emphasized an integrated management strategy addressing both articular and pulmonary disease and particularly recommended abatacept or rituximab for that dual-purpose control. EULAR and PANLAR, the reviewers observed, focused principally on rheumatoid arthritis management and did not provide dedicated RA-ILD treatment algorithms in the documents analyzed. The study team reported that the guideline panels differed in therapeutic priorities—some prioritized established ILD-directed immunomodulation, while others prioritized agents with favorable joint-and-lung profiles.
Across the guideline set, antifibrotic therapy was considered mainly in the context of progressive fibrosing disease. The authors noted that antifibrotic agents were not uniformly recommended as first-line therapy for all RA-ILD phenotypes; rather, panels discussed antifibrotics when fibrosing progression was documented. The abstracts and guideline summaries cited by the investigators framed antifibrotic use as a phenotype-specific consideration, tied to progressive fibrosis rather than universal application.
The reviewers attributed the observed differences to three interrelated factors: the stated scope of each guideline, the methodological approach taken by each panel, and the limited RA-ILD–specific evidence base. The study team observed that where direct, high-quality evidence was scarce, guideline panels relied more on extrapolation, expert opinion, or framework-specific priorities—leading to heterogeneity in screening, monitoring, and therapy recommendations. The authors reported that diagnostic recommendations were the most consistent because they rest on shared clinical tools and consensus practice; therapeutic choices varied where trial data are sparse or conflicting.
Limitations of the comparative review were reported by the authors: it is a narrative comparative review of guideline documents rather than a formal meta-analysis or a primary-data clinical study. The source did not report further methodological details such as grading systems used by each guideline group beyond noting methodological differences. The investigators concluded with a focused, actionable research gap: prospective comparative studies are needed to generate RA-ILD–specific data that can inform more consistent, evidence-based guideline recommendations. The article ends on that concrete next step—no broader regulatory milestones or timelines were documented in the source.